







































Malignancies among children and young people with
HIV in Western and Eastern Europe and Thailand
The European Pregnancy and Paediatric Infections Cohort
Collaboration (EPPICC) study groupM
Objectives: Investigate trends over time and predictors of malignancies among chil-
dren and young people with HIV.
Design: Pooled data from 17 cohorts in 15 countries across Europe and Thailand.
Methods: Individuals diagnosed with HIV and presenting to paediatric care less than
18 years of age were included. Time at risk began at birth for children with documented
vertically acquired HIV, and from first HIV-care visit for others. Children were followed
until death, loss-to-follow-up, or last visit in paediatric or adult care (where data after
transfer to adult care were available). Rates of reported malignancies were calculated
overall and for AIDS-defining malignancies (ADM) and non-AIDS-defining malignan-
cies (NADM) separately. Risk factors for any malignancy were explored using Poisson
regression, and for mortality following a malignancy diagnosis using Cox regression.
Results: Among 9632 individuals included, 140 (1.5%) were ever diagnosed with a
malignancy, of which 112 (80%) were ADM. Overall, the rate of any malignancy was
1.18 per 1000 person-years; the rate of ADM decreased over time whereas the rate of
NADM increased. Male sex, being from a European cohort, vertically acquired HIV,
current severe immunosuppression, current viral load greater than 400 copies/ml, older
age, and, for those not on treatment, earlier calendar year, were risk factors for a
malignancy diagnosis. Fifty-eight (41%) individuals with a malignancy died, a median
2.4 months (IQR 0.6–8.8) after malignancy diagnosis.
Conclusion: The rate of ADM has declined since widespread availability of combina-
tion ART, although of NADM, there was a small increase. Mortality following a
malignancy was high, warranting further investigation.
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Introduction
Cancer is relatively rare in childhood in the general
population, with the incidence rate to 19 years of age
across Western and Eastern Europe estimated at 0.14 per
1000 person-years [1]. However, as a result of immuno-
suppression, systemic inflammation, persistent HIV
viremia, and increased susceptibility to oncogenic viruses,
such as Epstein–Barr Virus (EBV) and human herpesvirus
8 (HHV-8), people with HIV are at higher risk of some
malignancies, including both those considered AIDS-
defining (ADM), such as Kaposi sarcoma and non-
Hodgkin lymphoma, and non-AIDS-defining (NADM),
such as Hodgkin lymphoma [2,3].
In adults living with HIV, studies have reported declining
incidence of ADM but increasing incidence of NADM in
recent years [4–6]. However, children who acquire HIV
vertically have lifelong exposure to the virus, and their
long-term risk of malignancies is unclear, with the only
studies that have followed them into young adulthood
limited by small sample sizes [7]. Studies in children have
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shown those on antiretroviral therapy (ART) and
initiating ART at younger ages are at lower risk [8–
10]. In this study, we describe rates, risk factors for
malignancy and mortality following a malignancy
diagnosis in children and young people in the European
Pregnancy and Paediatric Infections Cohort Collabora-
tion (EPPICC).
Methods
Seventeen observational cohorts in EPPICC from 15
countries across Europe and Thailand contributed
individual-level demographic, clinical, laboratory and
treatment-related data, which were pseudo-anonymized
and pooled electronically using a modified HIV Cohorts
Data Exchange Protocol (HICDEP, www.hicdep.org).
All cohorts received approval from local/national ethics
committees.
All children diagnosed with HIV, presenting to paediatric
HIV care before 18 years of age, and with more than 1 day
of follow-up were included. Time at risk began at birth
for those with vertically acquired HIV, or on the date first
seen in HIV care (defined as their first CD4þ cell count,
viral load, use of ARTor AIDS-defining event) for those
with other or unknown modes of acquisition as date of
HIV infection was often unknown. Data after transfer to
adult care were available for some individuals but if not
they were censored at their last visit in paediatric care.
Individuals were followed until death, loss to follow-up,
drop out from cohort (for example, if they moved clinic),
or their last visit prior to 1 October 2016.
None of the contributing cohorts are linked to cancer
registries, and so data on malignancy events were
collected from routine HIV healthcare records. Cervical
intraepithelial neoplasia, a precancerous condition, was
not included in the analysis. Malignancies were catego-
rized as ADM or NADM based on the US Centers for
Disease Control and Prevention (CDC) 2014 surveillance
criteria [11]. The number and rate (per 1000 person-
years) of malignancy events were summarized over
calendar time, overall and separately for ADM and
NADM. To allow for the possibility of multiple
malignancy diagnoses, rates were calculated as the
number of malignancy events divided by the total
duration of follow-up. Rates were presented among all
patients, as well as among patients on ‘stable ART’,
defined as those on ART for at least 6 months, who
currently had viral load 400 copies/ml or less and with no
HIV-related immunosuppression (defined based on
WHO criteria as CD4þ >35% for those age <1 year;
>30% for 1 to <3 years; >25% for 3-<5 years;
>500 cells/ml for 5 years [12]). Rates of specific
malignancies were presented where more than one event
was reported. Characteristics at the time of malignancy
diagnoses were compared among those with an ADM
or NADM, using a chi-squared or Fisher’s exact test
(where numbers were <5) for categorical variables and
Wilcoxon’s rank-sum test for continuous variables.
Risk factors for any malignancy were explored using
Poisson regression. Factors considered included sex,
region of cohort (UK/Ireland, Thailand, Russia/
Ukraine, rest of Europe), mode of HIV acquisition
(vertical vs. other). In addition, the following time-
updated characteristics were considered (with measure-
ments carried forward up to 12 months): current ART
status (not initiated ART vs. <6 months since ART
initiation vs. 6 months since ART initiation), current
calendar year (<1996 vs. 1996–2003 vs. 2004–2009 vs.
2010), current age (<5 vs. 5 to <10 vs. 10 to <15 vs.
15 years), current WHO immunological stage (severe
vs. not severe, with severe immunosuppression defined
based on WHO criteria as CD4þ <25% for those age
<1 year; <20% for age 1 to <3 years; <15% for 3 to
<5 years; <200 cells/ml or <15% for 5 years [12]),
current viral load (400 vs. >400 copies/ml), and
current BMI-for-age z-score (>2 vs. 2 to 2 vs.
<2, based on WHO reference data [13]). Ethnicity and
place of birth could not be included given that one of the
areas of focus was comparing by region, and there were
few children born abroad or from different ethnic groups
in Thailand and Russia/Ukraine; the effects of these
variables in the other cohorts were explored in a
supplementary analysis. Two-way interactions between
current ART status, calendar year and age were
considered, using a cut-off of P¼ 0.15 for inclusion.
Associations were explored using univariable models, and
all factors were included in a multivariable model.
Missing data on sex (missing for <1% of patients), mode
of HIV acquisition (5% of patients) and current
immunological stage (48% of patient-time), viral load
(48% of patient-time) and BMI-for-age z-score (66% of
patient-time) were imputed using multiple imputation
with chained equations; 20 imputed datasets were
created, and coefficients combined using Rubin’s rules
[14]. Risk factors for ADM and NADM were sub-
sequently explored separately, using the same methods.
The probability of all-cause mortality by 3 years after
malignancy diagnosis was estimated using Kaplan–Meier
methods, overall and by calendar year. Cox regression was
used to explore associations between mortality and the
following (at malignancy diagnosis, and categorized as
above if not specified): calendar year, malignancy type
(ADM vs. NADM), recent presentation to HIV care
(<6 months vs. 6 months), sex, region, mode of HIV
acquisition, age, ART status, WHO immunological stage
and BMI-for-age z-score.
Events occurring prior to the date first seen in HIV care
(n¼ 1) or with unknown diagnosis date (n¼ 3) in those
with other/unknown mode of infection were excluded
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from all analyses. Further, children with vertically
acquired HIV who had an event with unknown diagnosis
date (n¼ 4) were included in the overall malignancy rate
but excluded from analyses of the rate over calendar time
and of risk factors.
Statistical analyses were conducted using Stata 16.1
(StataCorp, College Station, Texas, USA).
Results
Overall, 9632 patients had more than 1 day of follow-up
in paediatric HIV care, and were therefore, included in
this analysis (Table 1). Two thousand and sixty-nine (21%)
patients were from UK/Ireland, 877 (9%) from Thailand,
2280 (24%) from Russia or Ukraine, and 4406 (46%) from
the rest of Europe. The mode of HIV acquisition was
documented as vertically acquired for 8352 (87%)
patients, blood transfusion for 607 (6%), sexual contact
for 83 (1%), other modes for 73 (1%), and was unknown
for 517 (5%). Three thousand eight hundred and ninety-
eight (40%) children were white, 2069 (21%) were black
African, 1268 (13%) were of other ethnicity, and ethnicity
was not reported for 2397 (25%). The median duration of
follow-up was 12.9 [interquartile range (IQR) 7.1–17.5]
years, with a total of 118 418 person-years of follow-up,
of which 87 072 person-years was among those born
within the country of their cohort and 28 946 person-
years those born outside. Eight thousand, seven hundred
and seventy-nine (91%) patients ever initiated ART.
Calendar year of entry to HIV care ranged from 1980 to
2016. At last follow-up, 4299 (45%) patients were still in
paediatric care, 1650 (17%) had been lost to follow-up,
747 (8%) had dropped out for other reasons, 915 (10%)
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n (%) or median (IQR)
Sex
Female 1090 (53%) 473 (54%) 1241 (54%) 2245 (51%) 5049 (52%)
Male 978 (47%) 404 (46%) 1036 (45%) 2160 (49%) 4578 (48%)
Unknown 1 (<0.5%) 0 3 (<0.5%) 1 (<0.5%) 5 (<0.5%)
Mode of HIV acquisition
Vertical 1922 (93%) 874 (100%) 2083 (91%) 3473 (79%) 8352 (87%)
Blood transfusion 40 (2%) 2 (<0.5%) 8 (<0.5%) 557 (13%) 607 (6%)
Sexual contact 0 1 (<0.5%) 37 (2%) 45 (1%) 83 (1%)
Other 1 (<0.5%) 0 16 (1%) 56 (1%) 73 (1%)
Unknown 106 (5%) 0 136 (6%) 275 (6%) 517 (5%)
Ethnicity
White 179 (9%) 0 264 (99%) 1455 (33%) 3898 (40%)
Black African 1616 (78%) 0 0 453 (10%) 2069 (21%)
Other 227 (11%) 877 (100%) 2 (<0.5%) 162 (4%) 1268 (13%)
Unknown 47 (2%) 0 14 (1%) 2336 (53%) 2397 (25%)
Born abroad
Yes 1164 (56%) 16 (2%) 6 (<0.5%) 964 (22%) 2150 (22%)
No 876 (42%) 782 (89%) 2262 (99%) 3377 (77%) 7297 (76%)
Unknown 29 (1%) 79 (9%) 12 (1%) 65 (1%) 185 (2%)
Region of country of birth if born abroad
Europe 22 (2%) 0 0 49 (5%) 71 (3%)
sub-Saharan Africa 654 (56%) 0 0 306 (32%) 960 (45%)
Other 29 (2%) 12 (88%) 0 64 (7%) 107 (5%)
Unknown 459 (39%) 2 (13%) 6 (100%) 545 (57%) 1012 (47%)
Entry to HIV carea
<1996 719 (35%) 319 (36%) 6 (<0.5%) 2192 (50%) 3233 (34%)
1996–2003 954 (46%) 466 (53%) 622 (27%) 1470 (33%) 3515 (36%)
2004–2009 311 (15%) 77 (8%) 1109 (45%) 521 (12%) 1927 (20%)
2010 85 (4%) 15 (2%) 633 (28%) 223 (5%) 957 (10%)
Ever initiated ART 1847 (89%) 877 (100%) 2085 (91%) 3970 (90%) 8779 (91%)
Age at ART initiation (years) 6.7 (2.4–11.2) 6.5 (2.3–9.6) 3.0 (1.0–6.5) 3.8 (0.9–8.9) 4.3 (1.2–9.1)
Duration of follow-up (years) 16.1 (11.2–17.9) 15.2 (11.0–18.3) 8.4 (4.7–11.9) 13.9 (7.1–18.3) 12.9 (7.1–17.5)
Current follow-up status
Still in paediatric care 837 (40%) 225 (26%) 1656 (73%) 1581 (36%) 4299 (45%)
Transferred to adult care 920 (44%) 70 (8%) 100 (5%) 931 (21%) 2021 (21%)
Dropped out of cohort 117 (6%) 338 (39%) 65 (3%) 227 (5%) 747 (8%)
Lost-to-follow-up 80 (4%) 170 (19%) 406 (18%) 994 (23%) 1650 (17%)
Died 115 (6%) 74 (8%) 53 (2%) 673 (15%) 915 (10%)
Data available after transfer to adult care 149 (16%) 70 (100%) 62 (62%) 272 (29%) 553 (27%)
Age at transfer to adult care (years) 17.7 (16.8–18.5) 17.7 (16.8–18.3) 17.9 (17.8–17.9) 18.7 (17.7–20.1) 18.1 (17.2–19.1)
Duration of follow-up in adult care (years) 2.8 (1.2–4.3) 2.8 (1.2–4.5) 1.4 (0.5–2.6) 3.6 (1.7–6.3) 2.8 (1.2–5.0)
ART, antiretroviral therapy; IQR, intequartile range.
had died in paediatric care, and the remaining 2021 (21%)
had transferred to adult care, of whom 553 (27%) had data
available after transfer with a median duration of adult
care follow-up of 2.8 (1.2, 5.0) years.
One hundred and forty (1.5%) patients had a malignancy
event (Table 2). No patient experienced more than one
event. Of the 140 events, 112 (80%) were ADM, with the
most common being non-Hodgkin lymphoma (n¼ 83)
and Kaposi sarcoma (n¼ 25). A further 27 (19%) were
NADM, including Hodgkin lymphoma (n¼ 15) and
hepatocellular carcinoma (n¼ 2, one each in patients co-
infected with hepatitis B and C).
Across all events, two (1%) patients were diagnosed with a
malignancy prior to entry to HIV care, 8 (6%) were
diagnosed at the same time as entry to HIV care, and 19
(14%) patients were diagnosed within 6 months. Among
these 29 patients, 22 acquired HIV through vertical
transmission [median age at malignancy diagnosis 5.1
(IQR 2.8–9.4) years], two through blood transfusion,
three through sexual contact, and the mode of acquisition
was unknown for three. Malignancy diagnoses among
those born abroad were more likely to be before or soon
after entering HIV care, compared with those born
within the country of cohort [12/31 (39%) vs. 17/106
(16%), P¼ 0.007]. Five events (four non-Hodgkin
lymphoma and one hepatocellular carcinoma) occurred
after transfer to adult care, at a median (IQR) age of 24.4
(18.8–24.9) years.
A higher proportion of those with an ADM were
diagnosed within 6 months of entry to HIV care [23%
(n¼ 26) vs. 7% (n¼ 2), P¼ 0.106] and a lower proportion
had previously been on ART [62% (n¼ 67) vs. 96%
(n¼ 26), P< 0.001], compared with those with an
NADM. Age [9.9 (IQR 4.6–14.6) vs. 10.1 (8.0–16.4)
years, P¼ 0.075], CD4þ% [15 (6–23) vs. 19 (9–25),
P¼ 0.273] and the proportion with severe immunosup-
pression (58 vs. 36%, P¼ 0.133) at malignancy diagnosis
were similar between with ADM and NADM.
Of the 25 children diagnosed with Kaposi sarcoma, 44%
were male, 40% were of black ethnicity, median age and
CD4þ% at malignancy diagnosis were 10.4 (5.4–14.3)
years and 6 (2–19) respectively. There were 11 events of
Burkitts lymphoma, of which 73% were in males and 45%
in those of white ethnicity, occurring at a median 14.3
(4.7–17.7) years of age and CD4þ% of 16 (10–30).
Overall, the rate of any malignancy was 1.18 [95%
confidence interval (CI) 1.00–1.40] per 1000 person-
years, and was 0.35 (0.18–0.68) among stable patients. Of
ADM specifically, the rate was 0.94 (0.79–1.14) and of
NADM was 0.23 (0.16–0.33). The rates of non-Hodgkin
lymphoma, Kaposi sarcoma and Hodgkin lymphoma
were 0.70 (0.57–0.87), 0.21 (0.14–0.31) and 0.13 (0.08–
0.21), respectively. The rate of any malignancy, ADM and
NADM by calendar time are shown in Fig. 1. The rate of
ADM was high and steady over time between 1990/1991
and 1996/1997 (P¼ 0.210; ranging between 2.37 and
3.02), after which it dropped dramatically, ranging
between 0.31 and 1.09 between 1996/1997 and 2014/
2015, with a slight continued decrease over time
(P¼ 0.064). The rate of NADM increased over time
from 0.21 in 1994/1995 to 0.53 in 2014/2015
(P¼ 0.060).
Risk factors for any malignancy are shown in Table 3. In
multivariable analysis, female individuals [adjusted rate
ratio (aRR) 0.63 (95% CI 0.45–0.89) vs. male individu-
als, P¼ 0.009] and those from the Thai cohort [aRR 0.16
(0.04–0.69) vs. UK/Ireland, P¼ 0.017] were at lower risk
of a malignancy. Individuals who did not acquire HIV
vertically were at lower risk than those who did so
vertically [other modes of infection aRR 0.58 (0.31–
0.98) vs. vertical, P¼ 0.049]. Those with current severe
immunosuppression [severe immunosuppression aRR
3.95 (2.48–6.29) vs. no severe immunosuppression,
P< 0.001] and viral load more than 400 copies/ml
[aRR 1.80 (1.01–3.71) vs. 400 copies/ml, P¼ 0.027]
were more likely to have a malignancy. There was
evidence of an interaction between current ART status
and each of current calendar year and current age (Fig. 2).
There was no change in risk over calendar time among
those who were not on ART (P¼ 0.414) or who had
been on ART less than 6 months (P¼ 0.999), but among
those on ART for more than 6 months, the risk decreased
over time [1996–2003 aRR 0.41 (0.23–0.74), 2004–
2009 aRR 0.25 (0.12–0.51), 2010 aRR 0.22 (0.10–
0.51) vs. <1996, P¼ 0.001]. There was a strong increase
in risk with increasing current age among those not on
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Table 2. Malignancy events.
Event N¼140 [n (%)]


















aOne patient had hepatitis B co-infection, and one had hepatitis C co-
infection.
bDescription of the eight other non-AIDS-defining malignancies:
brain ganglioglioma; ganglioneuroblastoma; chest wall tumour
(unspecified); disseminated adenocarcinoma; malignant fibrous his-
tiocytoma; neuroendocrine tumour of the pancreas; cystic teratoma;
acute T-lymphoblastic leukaemia.
ART or on ART for less than 6 months, although less of
an increase among those on ARTat least 6 months. There
was no evidence of an effect of current BMI-for-age z-
score (P¼ 0.114). In a supplementary analysis for
individuals from the UK/Ireland and rest of Europe
regions, there was no evidence of an effect of ethnicity or
place of birth in the adjusted model (P¼ 0.588, 0.955,
respectively, data not shown).
Risk factors for ADM and NADM are shown in
Supplementary Tables 1 and 2, http://links.lww.com/
QAD/C163. Risk factors for ADM were similar to those
for any malignancy. For NADM, only immunosuppres-
sion and mode of infection were found to be associated;
those with current severe immunosuppression were at
higher risk [aRR 2.91 (1.06–7.97) vs. not severe,
P¼ 0.038] as were, in contrast to risk factors for any
malignancy, those who did not acquire HIV vertically
[aRR 3.13 (1.01–9.74) vs. vertical, P¼ 0.049].
Overall, 58 (41%) patients with a malignancy event were
reported to have died. Three deaths occurred in children
with an unknown date of malignancy event, and the
remaining 55 died at a median 2.4 (IQR 0.6–8.8) months
(range 0.0–18.8 years) after malignancy diagnosis. Of 10
deaths among patients with an NADM, 8 (80%) were
reported to be because of their NADM, and two (20%)
because of an AIDS-defining event. Of 44 deaths among
patients with an ADM, 27 (61%) were because of an
AIDS-defining event, nine (20%) were reported as HIV-
related, two (5%) because of an invasive bacterial
infection, and the cause was unknown for six (14%).
The probability of death by 3 years after diagnosis was
41.1% (95% CI 33.1–50.3%). Those diagnosed with a
malignancy before 1996 were more likely to die by 3 years
[68.0% (51.9–83.1%)], with no change over time from
1996 onwards [30.6% (19.7–45.6%), 25.2% (12.1–
47.8%), 33.7% (17.5–58.6%) for 1996–2003, 2004–
2009 and after 2010, respectively] (Supplementary Figure
1, http://links.lww.com/QAD/C163). In multivariable
analysis, only earlier calendar year of malignancy diagnosis
and vertically acquired HIV were associated with higher
risk of mortality (Supplementary Table 3, http://
links.lww.com/QAD/C163).
Discussion
In this analysis of nearly 10 000 patients seen in paediatric
HIV care across Eastern and Western Europe and
Thailand, we assessed rates and risk factors for
malignancies and malignancy outcomes among children
and young people with HIV. The rate of ADM declined
markedly following the introduction and widespread
availability of combination ART for children in 1996,
with some evidence of an increase in NADM, although
rates were similar to those of any malignancy in the
general population [1]. Increased risk of a malignancy was
associated with older age among those not on treatment,
male sex, being from a European cohort, vertical HIV
acquisition, severe immunosuppression and viral load
greater than 400 copies/ml. High mortality was observed
following a malignancy diagnosis with no improvement
in recent years.
Across the whole time period, the rate of any malignancy
was 1.18 per 1000 person-years, approximately eight
times higher than the estimated 0.14 per 1000 person-
years for children and young people in the general
population in Europe [1]. The rate of ADM decreased
markedly in the late 1990s following the introduction and
widespread availability of paediatric combination ART, in
Malignancies among children with HIV EPPICC 1977
Fig. 1. Rates of malignancies over calendar time, overall and for AIDS-defining and non-AIDS-defining malignancies.
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Table 3. Risk factors for any malignancy.
Univariable Multivariable
Rate ratio 95% CI P Rate ratio 95% CI P
Demographics, at entry to HIV care
Sex
Female 0.59 0.42–0.83 0.002 0.63 0.45–0.89 0.009
Male 1.00 – 1.00 –
Region
UK/Ireland 1.00 – <0.001 1.00 – 0.017
Thailand 0.15 0.04–0.64 0.16 0.04–0.69
Russia/Ukraine 0.39 0.18–0.86 0.66 0.29–1.54
Rest of Europe 1.58 1.05–2.36 1.28 0.81–2.02
Mode of HIV acquisition
Vertical 1.00 – 0.055 1.00 – 0.049
Other 1.68 1.00–2.86 0.58 0.31–0.98
Time-updated
WHO immune stage
Not severe 1.00 – <0.001 1.00 – <0.001
Severe 4.56 3.11–6.69 3.95 2.48–6.29
Viral load
Suppressed 1.00 – 0.003 1.00 – 0.027
Not suppressed 2.42 1.37–4.27 1.80 1.01–3.71
BMI-for-age z-score
>2 1.00 – 0.023 1.00 – 0.114
2 to 2 2.29 0.38–13.75 2.01 0.32–12.53
<2 7.58 0.78–73.41 5.25 0.49–56.12
ART status
Not on ART 1.00 – 0.001
<6 months on ART 3.59 1.78–7.23
6 months on ART 1.68 1.10–2.57
Calendar year

















Effect of time-updated calendar year among those on ART














Effect of time-updated calendar year among those on ART















<5 1.00 – 0.033 Test for interaction: P¼0.088
5 to <10 1.29 0.80–2.07
10 to <15 1.46 0.90–2.38
15 2.02 1.26–3.25













Effect of time-updated age among those on ART



























CI, confidence interval; ART, antiretroviral therapy.
line with findings from adult studies [4–6]. Conversely,
the rate of NADM increased over time as reported
elsewhere [15], which may be because of increased
survival among those with HIV, although some NADM,
including Hodgkin lymphoma, are known to be related
to HIV [16]. Reassuringly, among virologically sup-
pressed, nonimmunosuppressed patients on ART in our
study, the rate of any malignancy was very low, 0.35 per
1000 person-years, although double the general popula-
tion rate. There may be reasons for this higher rate
beyond HIV status; key differences between our
population and that in the general population study [1]
are our inclusion of young people beyond 19 years of age
and our wider calendar time period. Further, there is
some evidence that the rate of malignancies is higher in
children from black ethnic groups in the general
population, and so higher than average rates may be
expected in our study, regardless of HIV infection [17].
The potential carcinogenic effect of ART is unclear [18].
In adjusted analysis, children from the Thai cohort were at
lower risk of a malignancy compared with those from
Europe. One explanation for this may be differing
exposures to oncogenic viruses. There is some evidence
of a lower seroprevalence of HHV-8, which is associated
with Kaposi sarcoma, in Thailand compared with Europe
and Africa [19,20]. A study estimating the risk of Kaposi
sarcoma in children and adolescents reported no cases in
Asia compared with rates between 11.4 and 85.8 per
100 000 person-years in sub-Saharan Africa and Europe
[21]. The small number of Kaposi sarcoma events here
precluded a similar analysis. Further, there is some
evidence of lower rates of malignancies in the general
paediatric population in Thailand compared with Europe
(0.10 and 0.14 per 1000 person-years, respectively)
[1,22].
The risk of a malignancy strongly increased with age
among those not on or who had only recently started
ART but there was less of an association, at least until
adolescence, among those on treatment. Increasing risk
among young people may be expected given the
increased risk of malignancy in the general population
in early adulthood [23]. Given that HIV infection is
lifelong, the full elevated long-term risk may yet emerge,
highlighting the importance of continued monitoring
throughout adulthood of those with HIV acquired in
childhood. Male individuals were at higher risk of ADM,
which may be expected given an excess of non-Hodgkin
lymphoma observed in the general male population [24].
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Fig. 2. Rate ratios for association between any malignancy and current calendar year (a) and current age (b) by antiretroviral
therapy status. Adjusted for sex, region, mode of HIV acquisition, WHO immune stage, viral suppression and BMI-for-age z-score.
Those with severe immune suppression and not virally
suppressed were at higher risk, in line with other studies
[9], reiterating the need for meeting UNAIDS targets for
ART coverage, improving adherence, and reducing late
diagnosis. Finally, those with vertically acquired HIV
were shown to be at higher risk of ADM, yet lower risk of
NADM, in adjusted analyses. Those with vertically
acquired HIVare more likely to have been born abroad in
our population, and so may have higher exposure to
endemic oncogenic viruses, such as HHV-8 and EBV
[25], although our analysis found no additional risk for
those born abroad. Further, they had a longer duration of
exposure to HIV. Reasons for the lower risk of NADM
are unclear but may be related to their younger age,
despite our adjustment for this.
Among those with a malignancy, all-cause mortality was
high, with over 40% of children and young people
reported to have died. In the general population,
mortality by 3 years after a childhood cancer diagnosis
in Europe has been estimated at 20% [26]. Although
outcomes improved following the roll out of combination
ART in 1996, worryingly, there was no improvement in
mortality over time following this in our study, with
approximately one-third of those diagnosed since 1996
dying within 3 years. This association was not explained
by key characteristics, such as age at diagnosis, type of
malignancy (ADM vs. NADM) or level of immunosup-
pression; vertically acquired HIV was the only other
factor explored which was associated. In adults with HIV,
malignancy outcomes have been shown to be broadly
similar to the general population, although with poorer
outcomes for some cancer types, including Hodgkin
lymphoma [27,28]. Delayed malignancy diagnosis was
believed to have contributed to poor outcomes in young
adults diagnosed with a malignancy in the UK (some of
whom are included here) [7]. Further, suboptimal
treatment, perhaps because of concerns over the use of
cancer treatment in children with immunosuppression
[29], may have also contributed to the high mortality. No
data on cancer treatment or stage at diagnosis, or any
biological samples, were available to assess this here.
Further, malignancy is associated with severe immuno-
suppression, which may have put patients at risk of dying
from other causes. Among survivors, there may be an
increased risk of secondary cancers, warranting regular
screening [30].
Our study has several other limitations. Firstly, none of
the cohorts were linked to cancer registries, so some cases
may have been missed, with under-ascertainment and
under diagnosis likely, especially in middle-income
settings. However, estimated incidence rates were similar
to other studies in children with HIV based on record
linkage [8,31]. Secondly, limited data on co-infections
with oncogenic viruses were available. Thirdly, despite
the large size of our cohort, our ability to determine
differences in risk factors for ADM and NADM was
limited by the relatively small number of NADM events,
and low power resulted in wide confidence intervals
when estimating rates over time. The major strength of
this study is the long duration of follow-up and long
calendar period covered as well as the inclusion of data
following transfer to adult care.
In conclusion, in this analysis of nearly 10 000 children
and young people with HIVacross Europe and Thailand,
we report a decline in the rates of ADM since the
introduction of combination ART, with the rate of any
malignancies among those on ART, virally suppressed and
immunologically well similar to that in the general
population. There was an increased risk with age, in
particular, in those not currently on ART, which requires
continued monitoring as young people with vertically
acquired HIV progress into adulthood. Linkage of
paediatric and adult registries, as well as HIV, malignancy
and death registries, is crucial. Even in recent years, one-
third of individuals with a malignancy died within 3 years
of diagnosis, which is very concerning; possible causes
should be explored and steps taken to address this.
Acknowledgements
We thank all the patients for their participation in these
cohorts, and the staff members who cared for them.
Author contributors: Writing Group [consisting of
Project Team first (ordered by contribution), followed
by other Writing Group members (ordered alphabetically
by country)].
Project Team: Elizabeth Chappell (EPPICC statistician),
Anna Turkova (Irkutsk AIDS Centre, Russia), Tessa
Goetghebuer (Hospital St Pierre Cohort, Brussels,
Belgium), Charlotte Jackson (EPPICC epidemiologist),
Elena Chiappini (Italian Register for HIV infection in
children, Italy), Luisa Galli (Italian Register for HIV
infection in children, Italy), Cosmina Gingaras (’Victor
Babes’ Hospital Cohort, Romania), Ali Judd (co-lead of
EPPICC).
Other Writing Group members: Vana Spoulou (Greek
cohort, Greece); Catiuscia Lisi (Italian Register for HIV
infection in children, Italy); Santa Ansone (Latvian
cohort, Latvia); Tom Wolfs (ATHENA paediatric cohort,
Netherlands); Magdalena Marczynska (Polish paediatric
cohort, Poland); Luminita Ene (’Victor Babes’ Hospital
Cohort, Romania); Yulia Plotnikova (Irkutsk AIDS
Centre, Russia); Evgeny Voronin (Republican Clinical
Infectious Diseases Hospital’ of the Ministry of Health of
the Russian Federation, St Petersburg, Russia); Anna
Samarina (The City HIV Centre, St Petersburg, Russia);
Gonzague Jourdain, Nicole Ngo-Giang-Huong
(Thailand Program for HIV Prevention and Treatment
(PHPT) Study Group, Thailand); Claudia Fortuny
1980 AIDS 2021, Vol 35 No 12
(CoRISPE-CAT, Catalonia cohort, Spain); Marisa Luisa
Navarro, Jose Tomas Ramos (CoRISPE-S, rest of Spain
cohort, Spain); Lars Naver (Karolinska University
Hospital, Stockholm, Sweden); Pierre-Alex Crisinel
(Swiss Mother and Child HIV Cohort Study,
Switzerland); Heather Bailey, Ruslan Malyuta, Alla
Volokha (Ukraine paediatirc HIV cohort, Ukraine);
Alasdair Bamford, Siobhan Crichton, Caroline Foster
(Collaborative HIV Paediatric Study (CHIPS) and
Integrated Screening Outcome Surveillance Service
(ISOSS), UK and Ireland); Claire Thorne (European
Collaborative Study); Intira Jeannie Collins, Carlo
Giaquinto, Diana M. Gibb [EPPICC/Paediatric Euro-
pean Network for the Treatment of AIDS (PENTA)].
EPPICC/PENTA Co-ordinating Team: Elizabeth Chap-
pell, Siobhan Critchton, Intira Jeannie Collins, Charlotte
Duff, Carlo Giaquinto, Ruth Goodall, Daniel Gomez-
pena, Charlotte Jackson, Ali Judd, Rebecca Lundin,
Laura Mangiarini, Edith Milanzi, Alessandra Nardone,
Claire Thorne.
Collaborating cohorts:
BELGIUM: Hospital St Pierre Cohort, Brussels: Tessa
Goetghebuer, MD, PhD; Marc Hainaut, MD PhD;
Evelyne Van der Kelen, Research nurse; Marc Delforge,
data manager.
GREECE: Greek cohort: Vana Spoulou.
ITALY: Italian Register for HIV infection in Children.
Coordinators: Maurizio de Martino, Luisa Galli (Flor-
ence), Pier Angelo Tovo, Clara Gabiano (Turin).
Participants: Ines Carloni (Ancona), Domenico Larovere
(Bari), Francesco Baldi, Angela Miniaci, Andrea Pession
(Bologna) Raffaele Badolato (Brescia), Grazia Pantò
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Deu, Esplugues (Clàudia Fortuny, Antoni Noguera-
Julian).
SPAIN: CoRISPE-S and Madrid cohort: Marı́a Jose
Mellado, Luis Escosa, Milagros Garcı́a Hortelano, Talı́a
Sainz (Hospital La Paz);Marı́a Isabel Gonzalez-Tome,
Pablo Rojo, Daniel Blazquez (Hospital Doce de Octubre,
Madrid); Jose Tomas Ramos (Hospital Clı́nico San
Carlos, Madrid); Luis Prieto, Sara Guillen (Hospital de
Getafe); Marı́a Luisa Navarro, Jesús Saavedra, Mar Santos,
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SWITZERLAND: Members of the Swiss HIV Cohort Study
(SHCS) and the Swiss Mother and Child HIV Cohort Study:
Aebi-Popp K, Anagnostopoulos A, Asner S, Battegay M,
Baumann M, Bernasconi E, B€oni J, Braun DL, Bucher
HC, Calmy A, Cavassini M, Ciuffi A, Duppenthaler A,
Dollenmaier G, Egger M, Elzi L, Fehr J, Fellay J, Francini
K, Furrer H, Fux CA, Grawe C, Günthard HF (President
of the SHCS), Haerry D (deputy of ‘Positive Council’),
Hasse B, Hirsch HH, Hoffmann M, H€osli I, Huber M,
Kahlert CR (Chairman of the Mother & Child
Substudy), Kaiser L, Keiser O, Klimkait T, Kottanattu
L, Kouyos RD, Kovari H, Ledergerber B, Martinetti G,
Martinez de Tejada B, Marzolini C, Metzner KJ, Müller
1982 AIDS 2021, Vol 35 No 12
N, Nicca D, Paioni P, Pantaleo G, Perreau M, Polli Ch,
Rauch A (Chairman of the Scientific Board), Rudin C,
Scherrer AU (Head of Data Centre), Schmid P, Speck R,
St€ockle M (Chairman of the Clinical and Laboratory
Committee), Tarr P, Thanh Lecompte M, Trkola A,
Vernazza P, Wagner N, Wandeler G, Weber R, Wyler CA,
Yerly S.
Funding: This study has been financed within the
framework of the Swiss HIV Cohort Study, supported
by the Swiss National Science Foundation (grant
#177499).
THAILAND: Program for HIV Prevention & Treatment
(PHPT). Participating hospitals: Lamphun: Pornpun
Wannarit; Phayao Provincial Hospital: Pornchai Techa-
kunakorn; Chiangrai Prachanukroh: Rawiwan Hansu-
dewechakul; Chiang Kham: Vanichaya
Wanchaitanawong; Phan: Sookchai Theansavettrakul;
Mae Sai: Sirisak Nanta; Prapokklao: Chaiwat Ngam-
piyaskul; Banglamung: Siriluk Phanomcheong; Chon-
buri: Suchat Hongsiriwon; Rayong: Warit
Karnchanamayul; Bhuddasothorn Chacheongsao:
Ratchanee Kwanchaipanich; Nakornping: Suparat Kan-
janavanit; Somdej Prapinklao: Nareerat Kamonpakorn,
Maneeratn Nantarukchaikul; Bhumibol Adulyadej: Pra-
paisri Layangool, Jutarat Mekmullica; Pranangklao:
Paiboon Lucksanapisitkul, Sudarat Watanayothin; Bud-
dhachinaraj: Narong Lertpienthum; Hat Yai: Boonyarat
Warachit; Regional Health Promotion Center 6, Khon
Kaen: Sansanee Hanpinitsak; Nong Khai: Sathit Potch-
alongsin; Samutsakhon: Pimpraphai Thanasiri, Sawitree
Krikajornkitti; Phaholpolphayuhasena: Pornsawan Atta-
vinijtrakarn; Kalasin: Sakulrat Srirojana; Nakhonpathom:
Suthunya Bunjongpak; Samutprakarn: Achara Puang-
sombat; Mahasarakam: Sathaporn Na-Rajsima; Roi-et:
Pornchai Ananpatharachai; Sanpatong: Noppadon
Akarathum; Vachira Phuket: Weerasak Lawtongkum;
Chiangdao: Prapawan Kheunjan, Thitiporn Suriyaboon,
Airada Saipanya.
Data management team: Kanchana Than-in-at, Nirattiya
Jaisieng, Rapeepan Suaysod, Sanuphong Chailoet,
Naritsara Naratee, and Suttipong Kawilapat.
UKRAINE: Paediatric HIV Cohort: Dr T. Kaleeva, Dr
Y. Baryshnikova (Odessa Regional Centre for HIV/
AIDS); Dr S. Soloha (Donetsk Regional Centre for HIV/
AIDS); Dr N. Bashkatova (Mariupol AIDS Center); Dr I.
Raus (Kiev City Centre for HIV/AIDS); Dr O.
Glutshenko, Dr Z. Ruban (Mykolaiv Regional Centre
for HIV/AIDS); Dr N. Prymak (Kryvyi Rih); Dr G.
Kiseleva (Simferopol); Dr Alla Volokha (Shupyk National
Medical Academy of Postgraduate Education); Dr Ruslan
Malyuta (Perinatal Prevention of AIDS Initiative, Odessa);
Dr H. Bailey, Prof Claire Thorne (UCL, London, UK).
Funding acknowledgement: PENTA Foundation.
UK AND IRELAND: Collaborative HIV Paediatric
Study (CHIPS): CHIPS is funded by the NHS (London
Specialised Commissioning Group) and has received
additional support from Abbott, Boehringer Ingelheim,
Bristol-Myers Squibb, GlaxoSmithKline, Gilead
Sciences, Janssen and Roche. The MRC Clinical Trials
Unit at UCL is supported by the Medical Research
Council (https://www.mrc.ac.uk) programme number
MC_UU_12023/26.
CHIPS Steering Committee: Hermione Lyall (chair),
Alasdair Bamford, Karina Butler, Katja Doerholt, Conor
Doherty, Caroline Foster, Ian Harrison, Julia Kenny,
Nigel Klein, Gillian Letting, Paddy McMaster, Fungai
Murau, Edith Nsangi, Katia Prime, Andrew Riordan,
Fiona Shackley, Delane Shingadia, Sharon Storey, Gareth
Tudor-Williams, Anna Turkova, Steve Welch. MRC
Clinical Trials Unit: Intira Jeannie Collins, Claire Cook,
Siobhan Crichton, Donna Dobson, Keith Fairbrother,
Diana M. Gibb, Ali Judd, Marthe Le Prevost, Nadine Van
Looy. Integrated Screening Outcome Surveillance Service
(ISOSS), UCL: Helen Peters, Kate Francis, Claire
Thorne.
Hospitals participating in CHIPS in 2019/20: University
Hospitals Birmingham NHS Foundation Trust, Birming-
ham: L. Thrasyvoulou, S. Welch; Brighton and Sussex
University Hospitals NHS Trust: K. Fidler; University
Hospitals Bristol NHS Foundation Trust, Bristol: J.
Bernatoniene, F. Manyika; Calderdale and Huddersfield
NHS Foundation Trust, Halifax: G. Sharpe; Derby
Teaching Hospitals NHS Foundation Trust: B. Sub-
ramaniam; Glasgow Royal Hospital for Children,
Glasgow: R. Hague, V. Price; Great Ormond Street
Hospital for Children NHS Foundation Trust, London: J,
Flynn, A, Cardoso, M, Abou – Rayyah, N, Klein, A,
Bamford, D, Shingadia; Oxford University Hospitals
NHS Foundation Trust, Oxford: S. Yeadon, S. Segal;
King’s College Hospital NHS Foundation Trust, London:
S. Hawkins; Leeds Teaching Hospitals NHS Trust, Leeds:
M. Dowie; University Hospitals of Leicester NHS Trust,
Leicester: S. Bandi, E. Percival; Luton and Dunstable
Hospital NHS Foundation Trust, Luton: M. Eisenhut; K.
Duncan; Milton Keynes General University Hospital
NHS Foundation Trust, Milton Keynes: L. Anguvaa, L.
Wren, Newcastle upon Tyne Hospitals NHS Foundation
Trust, Newcastle: T. Flood, A. Pickering; The Pennine
Acute Hospitals NHS Trust, Manchester: P. McMaster,
C. Murphy; North Middlesex University Hospital NHS
Trust, London: J. Daniels, Y. Lees; Northampton General
Hospital NHS Trust, Northampton: F. Thompson;
London North West Healthcare NHS Trust, Middlesex;
A. Williams, B. Williams, S. Pope; Barts Health NHS
trust, London Dr S. Libeschutz; Nottingham University
Hospitals NHS Trust, Nottingham: L. Cliffe, S. Southall;
Portsmouth Hospitals NHS Trust, Portsmouth: A.
Freeman; Raigmore Hospital, Inverness: H. Freeman;
Malignancies among children with HIV EPPICC 1983
Royal Belfast Hospital for Sick Children, Belfast: S.
Christie; Royal Berkshire NHS Foundation Trust,
Reading: A. Gordon; Royal Children’s Hospital,
Aberdeen: D. Rosie Hague, L. Clarke; Royal Edinburgh
Hospital for Sick Children, Edinburgh: L. Jones, L
Brown; Royal Free NHS Foundation Trust, London: M.
Greenberg; Alder Hey Children’s NHS Foundation
Trust, Liverpool: C. Benson, A. Riordan; Sheffield
Children’s NHS Foundation Trust, Sheffield: L. Ibber-
son, F. Shackley; University Hospital Southampton NHS
Foundation Trust, Southampton: S. Patel, J. Hancock; St
George’s University Hospitals NHS Foundation Trust,
London: K. Doerholt, K. Prime, M. Sharland, S. Storey;
Imperial College Healthcare NHS Trust, London:
E.G.H. Lyall, C. Foster, P. Seery, G. Tudor-Williams,
N Kirkhope, S Raghunanan; Guy’s and St Thomas’ NHS
Foundation Trust, London: Dr Julia Kenny, A. Callaghan;
University Hospitals of North Midlands NHS Trust,
Stoke On Trent: A Bridgwood, P. McMaster; University
Hospital of Wales, Cardiff: J. Evans, E. Blake; NHS
Frimley Health Foundation Trust, Slough: A. Yannoulias.
Funding statement: EPPICC receives funding from the
PENTA Foundation (http://penta-id.org), and received
support from the European Union’s Horizon 2020
research and innovation programme under Grant
Agreement No 825579 for the REACH study. The
MRC Clinical Trials Unit at UCL is supported by the
Medical Research Council (programme number
MC_UU_12023/26).
Conflicts of interest
C.T. has received grant funding from ViiV Healthcare via
the Penta Foundation (to UCL), and personally from
ViiV for participation on an advisory board. C.F. has
received funds for speaking at symposia organized on
behalf of Gilead Sciences.
References
1. Steliarova-Foucher E, Fidler MM, Colombet M, Lacour B,
Kaatsch P, Piñeros M, et al., ACCIS contributors. Changing
geographical patterns and trends in cancer incidence in chil-
dren and adolescents in Europe, 1991–2010 (Automated Child-
hood Cancer Information System): a population-based study.
Lancet Oncol 2018; 19:1159–1169.
2. Patel P, Hanson DL, Sullivan PS, Novak RM, Moorman AC,
Tong TC, et al. Incidence of types of cancer among HIV-
infected persons compared with the general population in
the United States, 1992-2003. Ann Intern Med 2008;
148:728–736.
3. Singh E, Naidu G, Davies M-A, Bohlius J. HIV-associated
malignancies in children. Curr Opin HIV AIDS 2017; 12:77–
83.
4. Hessol NA, Whittemore H, Vittinghoff E, Hsu LC, Ma D,
Scheer S, Schwarcz SK. Incidence of first and second primary
cancers diagnosed among people with HIV, 1985–2013: a
population-based, registry linkage study. Lancet HIV 2018;
5:e647–e655.
5. Shiels MS, Pfeiffer RM, Gail MH, Hall HI, Li J, Chaturvedi AK,
et al. Cancer burden in the HIV-infected population in the
United States. J Natl Cancer Inst 2011; 103:753–762.
6. Smith CJ, Ryom L, Weber R, Morlat P, Pradier C, Reiss P, et al.,
D:A:D Study Group. Trends in underlying causes of death in
people with HIV from 1999 to 2011 (D:A:D): a multicohort
collaboration. Lancet 2014; 384:241–248.
7. Chhabra S, Fidler S, Ayers S, Bower M, Lyall H, Foster C.
Malignancy and all-cause mortality; incidence in adolescents
and young adults living with perinatally acquired HIV. J Virus
Erad 2020; 6:30–33.
8. Bohlius J, Maxwell N, Spoerri A, Wainwright R, Sawry S, Poole J,
et al., for IeDEA-Southern Africa. Incidence of AIDS-defining
and other cancers in HIV-positive children in South Africa:
Record Linkage Study. Pediatr Infect Dis J 2016; 35:e164–
e170.
9. Kest H, Brogly S, McSherry G, Dashefsky B, Oleske J, Seage GR
3rd. Malignancy in perinatally human immunodeficiency virus-
infected children in the United States. Pediatr Infect Dis J 2005;
24:237–242.
10. Irira M, Ngocho JS, Youze J, Shayo I, Komba V, Minja L, et al.
Prevalence and outcome of HIV-associated malignancies among
HIV-infected childrenenrolled intocareatKilimanjaro Christian
Medical Center 2006 to 2014: a hospital-based retrospective
analytical study. J Pediatr Hematol Oncol 2020; 42:69–73.
11. Centers for Disease Control and Prevention. Revised surveil-
lance case definition for HIV infection–United States, 2014.
MMWR Morbid Mortal Wly Rep 2014; 63:1–10.
12. World Health Organization. WHO case definitions of HIV for
surveillance and revised clinical staging and immunological
classification of HIV-related disease in adults and children.
Geneva: World Health Organization; 2007.
13. World Health Organization. WHO child growth standards:
length/height-for-age, weight-for-age, weight-for-length,
weight-for-height and body mass index-for-age: methods and
development. Geneva: World Health Organization; 2006.
14. Rubin DB. Multiple imputation for nonresponse in surveys. Vol.
81. Hoboken, NJ: John Wiley & Sons; 2004.
15. Shiels MS, Engels EA. Evolving epidemiology of HIV-associated
malignancies. Current Opinion in HIV and AIDS 2017; 12:6–11.
16. Powles T, Robinson D, Stebbing J, Shamash J, Nelson M,
Gazzard B, et al. Highly active antiretroviral therapy and
the incidence of non-AIDS-defining cancers in people with
HIV infection. J Clin Oncol 2009; 27:884–890.
17. Sayeed S, Barnes I, Ali R. Childhood cancer incidence by ethnic
group in England, 2001–2007: a descriptive epidemiological
study. BMC Cancer 2017; 17:570.
18. Borges AH. Combination antiretroviral therapy and cancer
risk. Curr Opin HIV AIDS 2017; 12:12–19.
19. Ayuthaya PIN, Katano H, Inagi R, Auwanit W, Sata T, Kurata T,
et al. The seroprevalence of human herpesvirus 8 infection in
the Thai population. Southeast Asian J Trop Med Public Health
2002; 33:297–305.
20. Zhang T, Wang L. Epidemiology of Kaposi’s sarcoma-asso-
ciated herpesvirus in Asia: challenges and opportunities. J
Med Virol 2017; 89:563–570.
21. Pediatric AIDS-Defining Cancer Project Working Group for
IeDea Southern Africa TApHOD Cohere in EuroCoord. Rohner
E, Schmidlin K, Zwahlen M, Chakraborty R, Clifford G, et al.
Kaposi sarcoma risk in HIV-infected children and adolescents
on combination antiretroviral therapy from sub-Saharan Afri-
ca, Europe, and Asia. Clin Infect Dis 2016; 63:1245–1253.
22. Bidwell SS, Peterson CC, Demanelis K, Zarins KR, Meza R,
Sriplung H, et al. Childhood cancer incidence and survival in
Thailand: a comprehensive population-based registry analysis,
1990–2011. Pediatr Blood Cancer 2019; 66:e27428.
23. Cook MB, Dawsey SM, Freedman ND, Inskip PD, Wichner SM,
Quraishi SM, et al. Sex disparities in cancer incidence by period
and age. Cancer epidemiology, biomarkers & prevention: a
publication of the American Association for Cancer Research,
cosponsored by the American Society of Preventive Oncology
2009; 18:1174–1182.
24. Kaatsch P. Epidemiology of childhood cancer. Cancer Treat Rev
2010; 36:277–285.
25. Rohner E, Wyss N, Trelle S, Mbulaiteye SM, Egger M, Novak U,
et al. HHV-8 seroprevalence: a global view. Syst Rev 2014;
3:11–111.
1984 AIDS 2021, Vol 35 No 12
26. Gatta G, Botta L, Rossi S, Aareleid T, Bielska-Lasota M, Clavel J,
et al. Childhood cancer survival in Europe 1999–2007: results
of EUROCARE-5–—a population-based study. Lancet Oncol
2014; 15:35–47.
27. Cingolani A, Cozzi Lepri A, Teofili L, Galli L, Mazzotta V, Baldin
GM, et al., ICONA Foundation Study group. Survival and
predictors of death in people with HIV-associated lymphoma
compared to those with a diagnosis of lymphoma in general
population. PloS One 2017; 12:e0186549–e1186549.
28. Trickey A, May MT, Gill MJ, Grabar S, Vehreschild J, Wit F, et al.
Cause-specific mortality after diagnosis of cancer among HIV-
positive patients: a collaborative analysis of cohort studies. Int J
Cancer 2020; 146:3134–3146.
29. Stefan DC. Effect of HIV infection on the outcome of cancer
therapy in children. Lancet Oncol 2014; 15:e562–e567.
30. Bohlius J, Foster C, Naidu G, Sengayi M, Turkova A. Cancer in
adolescents and young adults living with HIV. Curr Opin HIV
AIDS 2018; 13:196–203.
31. Simard EP, Shiels MS, Bhatia K, Engels EA. Long-term
cancer risk among people diagnosed with AIDS during
childhood. Cancer Epidemiol Biomarkers Prev 2012; 21:
148–154.
Malignancies among children with HIV EPPICC 1985
